Pharmacy Tips and Reminders
e following strengths of Seroquel XR are preferred for Passport Health Plan: 150 mg, 200 mg,
300 mg, and 400 mg. PHP members on doses of Seroquel (immediate or extended release) less than 150 mg/day for more than 30 days will require prior authorization.
First line Pediculides for Passport Health Plan are Permethrin and Pyrethrins/Piperonyl butoxide. Second line Pediculicides- Ovide, Ulesfia, and Lindane 1% shampoo require trial and failure of a first line agent within the previous 45 days but no earlier than 21 days after the original fill of a first line agent.
Recent Federal Drug Administration (FDA) Advisories Affecting Network Pharmacies and Providers
e FDA recently issued the following advisories:
Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets and Phenobarbital Tablets Qualitest Pharmaceuticals issued a voluntary nationwide recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10mg / 500mg, NDC 0603-3888-20, 60 count, Lot Numbers T150G10B, T120J10E and T023M10A, and Phenobarbital Tablets, USP 32.4 mg, NDC 0603-5166-32, 1000 count, Lot Numbers T150G10B, T120J10E and T023M10A. An individual bottle of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10mg / 500mg, NDC 0603-3888-20, 60-count was found incorrectly labeled with a Phenobarbital Tablets, USP 32.4 mg, NDC 0603-5166-32, 1000 count label, printed with Lot Number T150G10B. Lots T120J10E and T023M10A used the same stock inventory of labels as Lot T150G10B and are potentially impacted.
Triad Alcohol Prep Pads, Alcohol Swabs, and Alcohol Swabsticks Recalled Due to Potential Microbial Contamination Certain Genentech medications are packaged with recalled Triad prep pads. Contaminated alcohol products could lead to life-threatening infections, especially in at risk populations. Patients and healthcare providers should not use the alcohol prep pads packaged with these medicines and should instead use an alternate alcohol prep pad that is not involved with the Triad Group recall.
Multaq (dronedarone) - Risk of Severe Liver Injury e FDA notified healthcare professionals and patients about cases of rare, but severe liver injury, including two cases of acute liver failure leading to liver transplant in patients treated with the heart medication dronedarone (Multaq). Information about the potential risk of liver injury from dronedarone is being added to the Warnings and Precautions and Adverse Reactions sections of the dronedarone labels.
Celerite Slimming Capsules: Undeclared Drug Ingredient FDA laboratory analysis confirmed that Celerite Slimming Capsules contain sibutramine, a controlled substance that was withdrawn from the market in October 2010 for safety reasons. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery